drugset / Trial / NCT05104775
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
Phase 1
Active not recruiting
33 enrolled
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients with relapsed/refractory hematologic malignancies will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.
Timeline
- Start
- 2022-02-09
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GNC-035 | Monoclonal antibody | — | Intravenous |